TransMedics Reports Fourth Quarter and Full Year 2025 Financial Results Andover, Mass. – February 24, 2026 – TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter and year ended December 31, 2025. Recent Highlights "We are very pleased with our fourth quarter and full year 2025 performance. These results reflect strong execu ...

ANDOVER, Mass., Feb. 27, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today issued additional information on the impact of the valuation allowance on deferred tax assets reported in the Company's fourth quarter financial results for the year ended December 31, 2025. As previously disclosed, in the fourth quarter of 2025, TransMedics released ...

Key Takeaways TMDX reported Q4 EPS of 57 cents, up 200% year over year, beating estimates by 39%.TransMedics posted 32% revenue growth in Q4, driven by the Organ Care System and logistics expansion.TMDX sees 2026 revenues of $727M-$757M, implying 20-25% growth over 2025 levels.TransMedics Group (TMDX) delivered earnings per share (EPS) of 57 cents in the fourth quarter of 2025, excluding a one-time benefit related to deferred tax assets, which surged 200% year over year. The figure surpassed the Zacks Conse ...

TransMedics Group (NasdaqGM:TMDX) Q4 2025 Earnings call February 24, 2026 04:30 PM ET Company ParticipantsAllen Gong - Vice President of Equity ResearchDaniel Markowitz - Equity Research AssociateGerardo Hernandez - CFOLaine Morgan - Associate VPWaleed Hassanein - President and CEONone - Company RepresentativeConference Call ParticipantsChris Pasquale - Partner and Senior Analyst of Medical Devices and SuppliesDavid Rescott - Senior Research AnalystJosh Jennings - Managing Director and Senior AnalystMatthew ...

TransMedics Group (NasdaqGM:TMDX) Q4 2025 Earnings call February 24, 2026 04:30 PM ET Company ParticipantsAllen Gong - Vice President of Equity ResearchDaniel Markowitz - Equity Research AssociateGerardo Hernandez - CFOLaine Morgan - Associate VPWaleed Hassanein - President and CEONone - Company RepresentativeConference Call ParticipantsChris Pasquale - Partner and Senior Analyst of Medical Devices and SuppliesDavid Rescott - Senior Research AnalystJosh Jennings - Managing Director and Senior AnalystMatthew ...

TransMedics Group (NasdaqGM:TMDX) Q4 2025 Earnings call February 24, 2026 04:30 PM ET Speaker9Good afternoon, and welcome to TransMedics' fourth quarter 2025 earnings conference call. At this time, all participants are in a listen-only mode. We will be facilitating a question-and-answer session towards the end of today's call. As a reminder, this call is being recorded for replay purposes. I would now like to turn the call over to Laine Morgan from the Gilmartin Group for a few introductory comments.Speaker ...

TransMedics Q4 2025 Performance Highlights February 24, 2026 2 TMDX Q4 2025 Performance – Key Highlights Product Revenue $100.4M 33.9% Y/Y Growth 14.5% Q/Q Growth 1 Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements. These forward-looking statements address various matters, including, among other things, future results and events, including financial guidance and projected estimates, and other statements that are predictive in nature. Investors are cau ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-38891 TransMedics Group, Inc. (Exact name of Registrant as specified in its Charter) Massachusetts 83-2181531 (State or other jurisd ...

Core Insights - TransMedics (TMDX) has received full and unconditional FDA Investigational Device Exemption (IDE) approval for its OCS ENHANCE Heart trial, allowing for full trial execution and patient enrollment [1][7] - This approval significantly de-risks the clinical roadmap for TransMedics and enhances confidence in its long-term growth potential, as successful trial execution could lead to broader clinical indications and increased utilization of the OCS platform [2][4] Company Overview - TransMedics currently has a market capitalization of $4.44 billion [6] - The OCS ENHANCE Heart trial is a two-part clinical program designed to redefine donor heart preservation, with an enrollment target of 650 patients [7][8] - The trial aims to compare the OCS Heart System with traditional cold storage methods, potentially generating a robust clinical dataset for heart transplantation [8][9] Market Trends - The global organ transplantation market was valued at approximately $18.59 billion in 2023 and is projected to grow to around $33.32 billion by 2032, with a compound annual growth rate (CAGR) of roughly 6.70% [10] - The growth in the organ transplantation market is driven by increasing chronic disease cases, advancements in immunosuppression therapies, and innovations in organ preservation technologies [11] Strategic Developments - In January, TransMedics announced a long-term lease for its new global headquarters and acquired adjacent land for an integrated campus, indicating its commitment to innovation and growth in organ transplant therapy [12]

Core Viewpoint - TransMedics Group, Inc. will release its financial results for the fourth quarter and full year 2025 on February 24, 2026, after market close, highlighting its ongoing commitment to transforming organ transplant therapy [1] Company Overview - TransMedics is a medical technology company focused on organ transplant therapy for patients with end-stage lung, heart, and liver failure [1] - The company is recognized as the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation [1] - TransMedics aims to address the unmet need for more and better organs for transplantation through its developed technologies that preserve organ quality and assess organ viability [1] Financial Results Announcement - The financial results will be announced after market close on February 24, 2026, with a conference call scheduled for 4:30 p.m. ET / 1:30 p.m. PT [1] - Investors can participate in the conference call by dialing specific numbers for domestic and international callers [1] - A live and archived webcast of the event will be available on the company's investor relations website [1]